Merck & Co., Inc. $MRK Stock Sold by Resona Asset Management Co. Ltd.

Resona Asset Management Co. Ltd. trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 1.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 780,662 shares of the company’s stock after selling 13,087 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Merck & Co., Inc. were worth $114,087,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Round Rock Advisors LLC grew its position in shares of Merck & Co., Inc. by 0.7% in the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after acquiring an additional 66 shares during the period. Cypress Wealth Services LLC increased its stake in shares of Merck & Co., Inc. by 0.5% during the 3rd quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock worth $1,960,000 after purchasing an additional 69 shares during the last quarter. Code Waechter LLC increased its stake in shares of Merck & Co., Inc. by 3.4% during the 3rd quarter. Code Waechter LLC now owns 2,179 shares of the company’s stock worth $317,000 after purchasing an additional 71 shares during the last quarter. Quest 10 Wealth Builders Inc. raised its holdings in shares of Merck & Co., Inc. by 12.2% in the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 699 shares of the company’s stock valued at $102,000 after purchasing an additional 76 shares during the period. Finally, Cascade Financial Partners LLC raised its holdings in shares of Merck & Co., Inc. by 0.5% in the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after purchasing an additional 80 shares during the period. 76.07% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Richard Deluca sold 58,185 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $148.01, for a total value of $8,611,961.85. Following the transaction, the executive vice president directly owned 112,955 shares of the company’s stock, valued at $16,718,469.55. This trade represents a 34.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.17% of the company’s stock.

Merck & Co., Inc. News Summary

These are some of the MRK news items that stood out recently:

Merck & Co., Inc. Stock Up 0.6%

NYSE MRK opened at $133.56 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.14 and a debt-to-equity ratio of 1.11. The company has a market cap of $329.26 billion, a price-to-earnings ratio of 137.69, a PEG ratio of 6.62 and a beta of 0.13. The company has a 50 day moving average of $145.28 and a 200-day moving average of $129.29. Merck & Co., Inc. has a 1-year low of $95.36 and a 1-year high of $156.92.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The company had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. During the same quarter last year, the business earned $2.58 earnings per share. Merck & Co., Inc.’s revenue was up 4.7% on a year-over-year basis. On average, equities research analysts expect that Merck & Co., Inc. will post 2.82 earnings per share for the current fiscal year.

Merck & Co., Inc. Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 15th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, December 15th. This represents a $3.52 annualized dividend and a dividend yield of 2.6%. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.85. Merck & Co., Inc.’s dividend payout ratio (DPR) is 350.52%.

Wall Street Analyst Weigh In

A number of research firms recently commented on MRK. Daiwa Securities Group upgraded Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target for the company in a report on Wednesday, August 12th. Guggenheim upped their price objective on Merck & Co., Inc. from $170.00 to $171.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Morgan Stanley cut their price objective on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. Leerink Partners lifted their target price on Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Finally, Sanford C. Bernstein lifted their target price on Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a “market perform” rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $155.74.

View Our Latest Research Report on MRK

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.